Cite

    Genovese, M., Hsia, E., Belkowski, S., Chien, C., Masterson, T., Thurmond, R., Manthey, C., Yan, D., Ge, T., & Greenspan, A. (2014). tHU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Antirheumatic Drug Therapy. Annals of the rheumatic diseases, 73, 224–225. http://access.bl.uk/ark:/81055/vdc_100135145910.0x000059